Generic price erosion wreaks more pharma havoc, with no end in sight
FiercePharma | May 01, 2017
A portfolio of 42 generic meds it acquired from Teva and Allergan last summer wouldn’t be meeting 2017 sales guidance thanks to a “tough pricing deflation cycle” in the U.S. copycat market.